Zentalis

Zentalis : Discovering and developing best-in-class small molecule therapeutics targeting fundamental biological cancer pathways. Pipeline includes ZN-c3, a WEE1 inhibitor for advanced solid tumors (currently enrolling a Ph 2 Fast Track trial in USC and planning to initiate a potentially registrational biomarker-driven trial), ZN-c5, an oral SERD for breast cancer, ZN-d5, a BCL-2 inhibitor for hematologic malignancies, and ZN-e4, an EGFR inhibitor for NSCLC. Multiple mono and combo trials are ongoing/planned across pipeline.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - Middle Atlantic
Clinical Stage
Phase l or ll
Disease Space
Oncology
Listing
Public, USA
Market Cap
1B +
Website:
Profiles:
Address:
530 Seventh Avenue, Ste 2201
Corner of 39 St
New York, NY 10018
United States

Company Participants at Zentalis R&D Day

  • Anthony Sun, CEO

Lead Programs

ZN-c5: Oral SERD

oral selective estrogen receptor degrader (SERD)

Indication Phase
Breast Cancer 1/2

ZN-c3: WEE1

oral inhibitor of WEE1

Indication Phase
Solid Tumors 1/2

ZN-d5: BCL-2

oral selective inhibitor of B-cell lymphoma 2 (BCL-2)

Indication Phase
Hematologic Malignancies IND

ZN-e4: EGFR

oral, small molecule inhibitor of mutant epidermal growth factor receptor (EGFR)

Indication Phase
NSCLC 1/2

Top 10 Holders of Zentalis Pharmaceuticals, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Fidelity Management & Research Co. LLC 13.15 5,926,318 331.93 13F 9/30/21
Matrix Capital Management Co. LP 9.65 4,349,279 243.60 13F 9/30/21
The Vanguard Group, Inc. 9.13 4,128,368 231.23 Funds 12/31/21
T. Rowe Price Associates, Inc. (Investment Management) 8.28 3,730,425 208.94 13F 9/30/21
Vanguard Group, Inc. (Subfiler) 6.75 3,040,636 170.31 13F 9/30/21
Tybourne Capital Management (HK) Ltd. 5.91 2,664,409 149.23 13F 9/30/21
Avidity Partners Management LP 5.54 2,493,800 139.68 13F 9/30/21
Viking Global Investors LP 4.70 2,118,284 118.65 13F 9/30/21
BlackRock Fund Advisors 3.31 1,489,949 83.45 13F 9/30/21
PRIMECAP Management Co. 2.96 1,335,620 74.81 13F 9/30/21
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2022 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.